![]()
|
|
||||||||
J. Biol. Chem., Vol. 282, Issue 30, 21592-21597, July 27, 2007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1
2
3


4
ois
5
From the
Centre of Microbial and Plant Genetics, Katholieke Universiteit Leuven, 3001 Heverlee, Belgium,
Department of Molecular Biology and Biotechnology, University of Sheffield, Sheffield S10 2TN, United Kingdom, and ¶BarrierTherapeutics nv, 2440 Geel, Belgium
The antifungal compound miconazole inhibits ergosterol biosynthesis and induces reactive oxygen species (ROS) in susceptible yeast species. To further uncover the mechanism of miconazole antifungal action and tolerance mechanisms, we screened the complete set of haploid Saccharomyces cerevisiae gene deletion mutants for mutants with an altered miconazole sensitivity phenotype. We identified 29 S. cerevisiae genes, which when deleted conferred at least 4-fold hypersensitivity to miconazole. Major functional groups encode proteins involved in tryptophan biosynthesis, membrane trafficking including endocytosis, regulation of actin cytoskeleton, and gene expression. With respect to the antifungal activity of miconazole, we demonstrate an antagonism with tryptophan and a synergy with a yeast endocytosis inhibitor. Because actin dynamics and induction of ROS are linked in yeast, we further focused on miconazole-mediated changes in actin cytoskeleton organization. In this respect, we demonstrate that miconazole induces changes in the actin cytoskeleton, indicative of increased filament stability, prior to ROS induction. These data provide novel mechanistic insights in the mode of action of a ROS-inducing azole.
Received for publication, September 5, 2006 , and in revised form, May 10, 2007.
* This work was supported in part by a grant from Instituut voor de Aanmoediging van Innovatie door Wetenschap en Technologie in Vlaanderen (IWT-Vlaanderen) (030023). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 Supported by a postdoctoral fellowship from Katholieke Universiteit Leuven (Industrial Research Fellow).
2 A senior non-clinical fellow of the Medical Research Council UK (G117/394).
3 Supported by a predoctoral fellowship from IWT-Vlaanderen.
5 Supported by a postdoctoral fellowship from IWT-Vlaanderen (OZM/030508).
4 To whom correspondence should be addressed: CMPG, Kasteelpark Arenberg 20, B-3001 Heverlee, Belgium. Tel.: 32-16-32-96-82; Fax: 32-16-32-19-66; E-mail: bruno.cammue{at}biw.kuleuven.be.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |